China channel feed

Prep­ping a cross-Pa­cif­ic move, Or­biMed-backed Apol­lomics bags $100M Se­ries B for I/O com­bos

7 years ago
Financing

With ear­ly-stage stud­ies un­der­way, Con­nect Bio­phar­ma­ceu­ti­cals clos­es $55M round to ad­vance im­mune mod­u­la­tors

7 years ago
Financing
Startups

Chi­na green­lights sec­ond home­grown PD-1 in 10 days as In­novent cel­e­brates its first drug OK with Eli Lil­ly

7 years ago
Pharma

What oth­er biotech news have you been miss­ing? A big Chi­na IPO and more

7 years ago
Financing

Fi­bro­Gen, As­traZeneca score Chi­na ap­proval for ane­mia drug ahead of piv­otal US da­ta

7 years ago
Pharma

Jun­shi wins the race for first made-in-Chi­na PD-1 ap­proval as ex­ecs reap $394M IPO har­vest

7 years ago
Financing
Pharma

Broad­en­ing its on­col­o­gy fo­cus, In­novent adds three In­cyte drugs to port­fo­lio for $40M cash

7 years ago
R&D
Pharma

WuXi AppTec cruis­es to­ward a steady de­but in Hong Kong stock ex­change, end­ing flat on IPO price

7 years ago
Financing

Join­ing hunt for hep B cure, Brii Bio inks maid­en deals fea­tur­ing VBI, Vir, WuXi with a big ap­petite for more

7 years ago
Pharma

Can a $1B IPO at­tract leery in­vestors on HKEX? WuXi AppTec is set to find out

7 years ago
Financing

Bio­Haven hopes to soothe Chi­nese headaches with Shang­hai sub­sidiary

7 years ago

At the cen­ter of a glob­al tem­pest, Jiankui He de­fends edit­ing the genes of 2 new­borns

7 years ago

In a land­mark first, Chi­nese sci­en­tist claims birth of ge­net­i­cal­ly mod­i­fied ba­bies — and all hell breaks loose

7 years ago

Seek­ing an edge in the glob­al I/O race, Al­pham­ab On­col­o­gy loads up $100M-plus from mar­quee back­ers

7 years ago
Financing

CStone braves the HKEX with late-stage plans brew­ing for new­ly beefed up I/O pipeline

7 years ago
Financing

In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na loom­ing

7 years ago
R&D

Fi­nal­ly! In­novent hikes on Hong Kong de­but amid cloudy mar­ket sen­ti­ments

7 years ago
Financing

Feds charge a group of Genen­tech vets with an­oth­er scheme to steal trade se­crets — this time to help a Tai­wanese biotech

7 years ago

WuXi dives in­to com­pu­ta­tion­al drug dis­cov­ery, launch­es New York-based JV with Schrödinger

7 years ago
Financing
AI

Terns scores $80M in Se­ries B fi­nanc­ing led by Vi­vo, Or­biMed

7 years ago
Financing

A pho­to log of my week in Shang­hai, host­ing the first an­nu­al US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit

7 years ago

Hong Kong IPO de­liv­ers $421M to In­novent as an­oth­er one of Chi­na's biotech uni­corns hauls in big mon­ey

7 years ago
Financing

In­novent to seek $400M-plus on Hong Kong IPO, re­ports say; will it re­vive biotech's for­tunes on HKEX?

7 years ago
Financing

#BI­IS18 In­ter­view: Or­biMed Asi­a's Jonathan Wang on his up­bring­ing, de­cid­ing against a con­sult­ing ca­reer, blunt ad­vice for Chi­nese en­tre­pre­neurs, and more

7 years ago
People
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times